HeartSciences Income Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan '25 Jan 31, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022	Apr '21 Apr 30, 2021	Apr '20 Apr 30, 2020
Revenue	-	0.02	0.01	0.01	0.03	0.06
Revenue Growth (YoY)	-	261.17%	-64.17%	-43.86%	-60.11%	-
Cost of Revenue	-	0.01	0	0.01	0.01	0.05
Gross Profit	-	0.01	0	0.01	0.01	0.02
Selling, General & Admin	3.81	3.44	3.65	1.71	0.87	1.8
Research & Development	4.5	2.88	2.46	3	1.71	2.04
Operating Expenses	8.31	6.32	6.12	4.72	2.58	3.84
Operating Income	-8.31	-6.31	-6.11	-4.71	-2.57	-3.82
Interest Expense	-0.34	-0.35	-0.24	-0.37	-0.13	-0
Other Non Operating Income (Expenses)	0.14	0.05	0	0	-0	-0
EBT Excluding Unusual Items	-8.52	-6.61	-6.35	-5.08	-2.7	-3.82
Gain (Loss) on Sale of Assets	-	-	-	-	0	-0.01
Other Unusual Items	-	-	-	0.25	0.25	0.02
Pretax Income	-8.52	-6.61	-6.35	-4.83	-2.45	-3.81
Net Income	-8.52	-6.61	-6.35	-4.83	-2.45	-3.81
Net Income to Common	-8.52	-6.61	-6.35	-4.83	-2.45	-3.81
Shares Outstanding (Basic)	1	0	0	0	0	0
Shares Outstanding (Diluted)	1	0	0	0	0	0
Shares Change (YoY)	290.34%	343.39%	139.56%	0.15%	-	-
EPS (Basic)	-10.22	-18.74	-79.92	-145.48	-74.00	-115.01
EPS (Diluted)	-10.22	-18.74	-79.92	-145.48	-74.00	-115.01
Free Cash Flow	-7.45	-6.13	-5.79	-3.65	-2.45	-3.85
Free Cash Flow Per Share	-8.94	-17.40	-72.85	-109.86	-74.02	-116.22
Gross Margin	-	67.31%	45.71%	45.11%	58.35%	27.61%
Operating Margin	-	-33901.99%	-118698.33%	-32765.60%	-10030.18%	-5948.99%
Profit Margin	-	-35511.87%	-123384.27%	-33592.57%	-9577.29%	-5937.99%
Free Cash Flow Margin	-	-32981.93%	-112463.79%	-25367.54%	-9580.56%	-6000.78%
EBITDA	-8.27	-6.28	-6.09	-4.68	-2.53	-3.77
D&A For EBITDA	0.04	0.03	0.03	0.03	0.03	0.05
EBIT	-8.31	-6.31	-6.11	-4.71	-2.57	-3.82

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q